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The structure of the receptor for advanced glycation end products (RAGE) in complex with a peptide contain-
ing an N3-carboxy-ethyl-lysine (CEL) (Xue et al., 2011) shows how the modification of the lysine side chain is
recognized without specific interaction with the peptide.Life in a cell depends on a multitude of
chemical reactions and molecular inter-
actions that all occur in parallel. While
some of these processes can be sepa-
rated from others by confining them to
specific organelles, many interactions
and chemical reactions take place at the
same time in the same cellular compart-
ment. To prevent unwanted or even
harmful cross-reactions, the interaction
between biological macromolecules and
their substrates or ligands has to be very
specific. In contrast to these very specific
interactions that regulate the normal life of
a cell, for certain molecular processes it is
important to be rather unspecific. A large
class of processes dependent on the
recognition of multiple, not very specific
input signals that have to be turned into
a specific output signal are quality control
processes that monitor the general state
of a cell or a tissue, or of the entire
organism. In the cellular environment,
a large set of proteins is dedicated to
monitor the state of the cell and to detect,
for example, imbalances in the cellular
level of important substrates, formation
of protein aggregates, or DNA or organ-
elle damage.
Certain types of cells also monitor
extracellular stress signals that would,
for example, indicate the presence of
pathogens. One particular stress moni-
toring system that has been studied for
many years is the AGE-RAGE system.
AGE is the abbreviation for advanced
glycation end products, and RAGE is the
receptor for these substrates that are
created by nonenzymatic glycation reac-
tions of proteins (Neeper et al., 1992).
It has been demonstrated that the AGE-
RAGE interaction can affect the severity
of several diseases, including diabetes,Alzheimers disease, and cancer (Logsdon
et al., 2007; Yan et al., 2010).
Despitemany yearsof extensive studies
of the AGE-RAGE system, only limited
structural information has been available
to explain how the RAGE receptor local-
ized on cell surfaces interacts with and
identifies AGE products. In this issue of
Structure, Xue et al. (2011) describe the
NMR solution structure of a recognition
domain of the receptor in complex with
a peptide containing N3-carboxy-ethyl-
lysine (CEL). This structure provides
detailed information about how the very
diverse group of glycation products that
is present in tissues and in the blood-
stream is recognized by the receptor.
N3-carboxy-ethyl-lysine and N3-carboxy-
methly-lysine (CML) are two of the most
important modifications recognized by
the RAGE receptor. The underlying mech-
anistic problem is that, due to the high
abundance of lysine residues in proteins,
their glycation products can occur in
many different secondary and tertiary
structure environments that should not
interfere with the ability of the receptor to
recognize and bind the modified lysine.
Surprisingly, free N3-carboxy-ethyl-lysine
and N3-carboxy-methly-lysine do not
interact with the receptor, showing
that modified residues are recognized
only when presented in the context of
a peptide or a protein. The receptor itself
is a member of the immunoglobulin
superfamily with three extracellular
immunoglobulin domains, of which only
the V-domain is involved in AGE binding.
To investigate the specificity of the
interaction, Xue et al. (2011) first per-
formed interaction studies with different
peptides differing in sequence and in the
modification state of their lysines. In theseStructure 19, May 11, 2011experiments, they could confirm that the
primary sequence does not significantly
influence the binding affinity. However,
modification of the lysine contained within
these sequences increased the affinity
6 to 7 fold. This increase was virtually
the same for both CEL and CML
modifications. To understand the molec-
ular origin of the specific recognition of
the modification irrespective of the
primary sequence in which the modified
lysines are embedded in, Xue et al.
(2011) solved the NMR structure of
a complex of the V-domain of RAGE and
a seven amino-acid CEL peptide derived
from human serum albumin, representing
one of the major glycation products found
in humans. The CEL peptide binds to
a positively charged surface on the
V-domain in a bent conformation with
the modified lysine being in the center.
Of central importance for the interaction
between both molecules is the negatively
charged carboxyethyl head group of CEL
that interacts with a shallow positively
charged groove on the surface of the
V-domain. The structure also reveals
why RAGE identifies a modified CELpep-
tide but interacts more weakly with an
unmodified peptide in which the lysine is
replaced with a negatively charged gluta-
mic acid residue; the CEL moiety binds in
an extended conformation and, since it is
significantly longer than the side chain of
a glutamic acid, the CEL can make more
hydrophobic contacts with the binding
site, leading to an increased affinity. The
exact geometry of the bound CEL group
also explains why CML and CEL, which
contains an extra methyl group, bind
with virtually the same affinity, since this
extra methyl group is not part of the
binding interface.ª2011 Elsevier Ltd All rights reserved 601
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PreviewsThe structure further reveals why the
modified lysines must be embedded
within a peptide when binding to RAGE
without a significant effect of the exact
sequence of the peptide. The V-domain
makesmainly contacts with the backbone
of the peptide and provides some addi-
tional hydrophobic interaction surfaces
that do not seem to provide specificity.
This is most likely caused by the shallow
groove that constitutes the binding site
and that lacks deep pockets that could
be used for specific interaction, for
example, with large aromatic amino acid
side chains.
The structure and binding data pre-
sented in the current paper nicely demon-
strate that RAGE acts as a pattern recog-
nition receptor that recognizes a negative
charge presented at a certain distance
from the backbone of the embedding
peptide. Yet the overall binding affinity of
a CEL- or CML-modified peptide is too602 Structure 19, May 11, 2011 ª2011 Elsevilow to explain their biological effects.
Xue et al. (2011) suggest that this problem
is solved by the oligomerization of RAGE
in the membrane, which allows it to bind
to proteins with more than one glycation
site with a much higher affinity. Since the
number of multiple modified proteins
increases during stress conditions, this
weak binding per binding site in combina-
tion with the oligomerization allows the
building of a receptor that gets activated
only after a certain level of glycation
products has been reached.
AGE receptors are expressed on the
surface of monocytes, macrophages,
endothelial cells, pericytes, podocytes,
astrocytes, and microglia, and their
activation in these cells leads to increased
expression of extracellular matrix pro-
teins, vascular adhesion molecules, cyto-
kines, and growth factors (Thornalley,
1998). Since these processes can lead to
inflammation and negatively influenceer Ltd All rights reservedthe progress of diseases such as diabetes
or cancer, inhibitors for RAGE are of clin-
ical relevance. The new structure and
characterization of the binding behavior
of different peptides now provides a basis
for starting design experiments to inhibit
the AGE-RAGE interaction.REFERENCES
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